Complete Omics
Complete Omics Inc. is a leader in clinical proteomics and multi-omics molecular diagnostics, dedicated to advancing personalized medicine through innovative multi-omics platforms and clinical applications. The company has established several robust patented and proprietary platforms, including Deep-Seq for genomics, MetaBoost for metabolomics, Valid-NEO for neoantigen detection, and DEEPER-Seq for ultra-rare mutation calling, supporting research and clinical diagnostics. With a strong focus on clinical impact, they have achieved milestones such as obtaining California Clinical Laboratory License, CLIA and CAP certifications, and forming strategic partnerships to revolutionize disease research and treatment. Their mission is to enable clinical advancements and improve patient outcomes through cutting-edge omics technologies.
Industries
Nr. of Employees
small (1-50)
Complete Omics
Products
Patented method for neoantigen analysis enabling direct cell-surface quantification
An issued U.S. patent covering an analytical method and system for direct detection and absolute quantification of neoantigens presented on cell surfaces from low-input clinical samples, intended to support companion-diagnostic and translational workflows.
Targeted NGS architecture for low-input and damaged samples
Targeted NGS approach employing barcoded single-strand library preparation and dual-RNA-probe capture to improve recovery and sensitivity for ultra-rare variant detection in FFPE, plasma, ancient, or otherwise degraded clinical samples.
Patented method for neoantigen analysis enabling direct cell-surface quantification
An issued U.S. patent covering an analytical method and system for direct detection and absolute quantification of neoantigens presented on cell surfaces from low-input clinical samples, intended to support companion-diagnostic and translational workflows.
Targeted NGS architecture for low-input and damaged samples
Targeted NGS approach employing barcoded single-strand library preparation and dual-RNA-probe capture to improve recovery and sensitivity for ultra-rare variant detection in FFPE, plasma, ancient, or otherwise degraded clinical samples.
Services
Clinical multi-omics diagnostic testing
Laboratory-based clinical testing combining proteomics, genomics, and metabolomics for disease diagnostics, biomarker measurement, and translational research reporting.
Neoantigen detection and quantification service
Direct detection and absolute quantification of tumor neoantigens from limited biopsy material to support personalized immunotherapy development and patient selection.
Genomics services (targeted, exome/genome, RNA-Seq, methyl-Seq, single-cell, damaged-sample workflows)
End-to-end NGS services including targeted capture for damaged or low-input samples, whole-exome/genome sequencing, RNA-Seq, methylation sequencing, ChIP-Seq, and single-cell genomics.
Proteomics services (quantitative, PTM mapping, immunopeptidomics, single-cell)
Comprehensive proteomics services including relative and absolute quantitation, PTM mapping, immunopeptidome profiling, host-cell protein analysis, and single-cell proteomics.
Metabolomics and lipidomics analysis services
Targeted and untargeted small-molecule and lipid profiling using sensitive workflows and chemical derivatization to enhance detection for research and translational applications.
Regulatory training and CLIA/CAP workflow training
Hands-on training in CLIA/CAP–compliant laboratory workflows, clinical assay development, QA/QC documentation, and audit preparation delivered within an accredited laboratory environment.
Clinical multi-omics diagnostic testing
Laboratory-based clinical testing combining proteomics, genomics, and metabolomics for disease diagnostics, biomarker measurement, and translational research reporting.
Neoantigen detection and quantification service
Direct detection and absolute quantification of tumor neoantigens from limited biopsy material to support personalized immunotherapy development and patient selection.
Genomics services (targeted, exome/genome, RNA-Seq, methyl-Seq, single-cell, damaged-sample workflows)
End-to-end NGS services including targeted capture for damaged or low-input samples, whole-exome/genome sequencing, RNA-Seq, methylation sequencing, ChIP-Seq, and single-cell genomics.
Proteomics services (quantitative, PTM mapping, immunopeptidomics, single-cell)
Comprehensive proteomics services including relative and absolute quantitation, PTM mapping, immunopeptidome profiling, host-cell protein analysis, and single-cell proteomics.
Metabolomics and lipidomics analysis services
Targeted and untargeted small-molecule and lipid profiling using sensitive workflows and chemical derivatization to enhance detection for research and translational applications.
Regulatory training and CLIA/CAP workflow training
Hands-on training in CLIA/CAP–compliant laboratory workflows, clinical assay development, QA/QC documentation, and audit preparation delivered within an accredited laboratory environment.
Expertise Areas
- Clinical proteomics and diagnostics
- Neoantigen discovery and quantitative validation
- Multi-omics integration (genomics, proteomics, metabolomics)
- Targeted and low-input NGS for damaged samples
Key Technologies
- Mass spectrometry–based proteomics
- Immunopeptidomics (mass-spectrometry detection of presented peptides)
- Targeted capture NGS with dual-RNA-probe methodology
- Barcoded single-strand library preparation for low-input DNA